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It has been argued that “lamp-post research” is the main
culprit in the lack of major breakthroughs in neuropsychi-
atric drug discovery. An old joke goes like this. A drunk loses
his keys and looks for them under a lamp-post. A passerby
asks what he is doing. He answers: “Looking for my keys
that I lost in a dark alley two blocks away.” “Then why
are you looking for them under this lamp-post?” wonders
the passerby. “Because I can see much better here.” Not
all researchers looking for novel neuropsychiatric pharma-
cological treatments are all drunks, but the alternative to
lamp-post research (which mostly generates “me-too” drugs
rather than entirely new compounds) appears to be even less
rational—it typically involves serendipity.
S e v e r a ls t r a t e g i e sh a v eb e e np r o p o s e dt oo v e r c o m e
reliance on pure serendipity, which occurs too rarely
to be counted on as a consistent source of drug dis-
covery. These strategies include cell-phenotype-based and
organism-phenotype-based approaches to the rationaliza-
tion of serendipity for drug discovery. Phenotype-based
approachesto drug discovery rely on the notion that putative
therapeutic molecules can be discovered in the absence of
any knowledge about a disease mechanism (i.e., molecular
target) if these molecules are capable of reversing a disease
phenotype. A historical example of serendipitous organism-
phenotype-based approach is the discovery of the ﬁrst
antidepressant agents. Brieﬂy, in the search for a tuberculo-
static at the end of World War II, stocks of the leftover rocket
propellant hydrazine were used to produce its chemical
derivatives, isoniazid and iproniazid, which were found to be
potently tuberculostatic. Physicians who more than 60 years
ago used these drugs for treatment of tuberculosis observed
that,inadditiontothehealingoftubercularlesions,isoniazid
and even more so, iproniazid, produced favorable mental
“side eﬀects.” This serendipitous organism-phenotype-based
discoveryledtothetestingofiproniazidindepressedpatients
and ﬁnding its antidepressant action.
Recent indications of putative mechanisms responsi-
ble for the cooccurrence of cardiovascular and psychi-
atric/neurologicaldisorderspointtoanadditionalpossibility
for improving the process of serendipity rationalization in
drug discovery—by focusing on the cooccurrence of these
disorders.
As an example, one could focus on the cooccurrence
of major depression (MD) and coronary heart disease
(CHD), in which depression is independently associated
with increased cardiovascular morbidity and mortality.
Serendipity could be rationalized by speciﬁcally targeting
patients with cooccurring MD and CHD (or alternatively
using animal models of this cooccurrence) and applying
the CHD-phenotype-based approach in evaluating drugs
(standard or novel/experimental) administered primarily for
the treatment of the MD component of the cooccurrence. A
successful screen performed in this manner could lead to the
discovery of novel families of cardiovascular drugs. Alterna-
tively, one could use the MD-phenotype-based approach in
evaluating drugs for the treatment of the CHD component
of this cooccurrence to ﬁnd novel antidepressants. For
such an approach to be successful, no initial knowledge is
required about the putative mechanistic links between MD
and CHD. Once eﬀective drugs/molecules are identiﬁed,2 Cardiovascular Psychiatry and Neurology
this knowledge could be used to elucidate the participating
biological/molecular mechanisms. Similar approaches could
be developed for other cooccurring cardiovascular and
psychiatric/neurological disorders.
The current establishment of a new network of NIH-
(National Institutes of Nealth-) supported Clinical and
Translational Research Centers (CTSCs) in the USA empha-
sizes a renewed interest in fostering closer ties between basic
and clinical research. If these ties succeed in rationalizing
serendipity in the search for novel neuropsychiatric and
cardiovascular pharmacological treatments, the new CTSCs
couldprovetobeawayoutofdiscreditedlamp-postresearch
and also a way to stop relying on the serendipitous discov-
eries that have proved so scarce in the past. Cardiovascular
PsychiatryandNeurology looks forwardtothe resultsofthese
future studies.
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